Please assess the completion status of the following clinical trial:

Trial Title: Minocycline Therapy for Management of Adverse Radiation Effects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age range: 18 - 90 years~* Males and females.~* Patients must have undergone cranial radiosurgery.~* MRI evidence supporting the diagnosis of ARE and/or surgical biopsy evidence of necrosis without tumor at ≤2 months before study entry.~* Karnofsky performance status of ≥60,~* With or without evidence of progressive neurologic signs or symptoms appropriate to the location of the ARE, and no previous bevacizumab therapy.~* With or without previous chemotherapy for their tumor.~* Routine laboratory study results with bilirubin ≤1.5 times the upper limit of normal, aspartate aminotransferase and/or alanine aminotransferase \<2.5 times the upper limit of normal, creatinine \<2.0 times the upper limit of normal.~* Patients with a history of seizures will be required to be receiving anticonvulsant therapy and to be seizure-free for ≥1 week before study.~Exclusion Criteria:~* Significant mass effect requiring resection (as assessed by a clinical neurosurgeon)~* Known hypersensitivity to tetracyclines~* Women of childbearing age must be non-lactating and have a negative urine pregnancy test (adequate birth control includes use of intra uterine device, or a barrier method, e.g. condom, diaphragm). The results of animal studies indicate that tetracyclines cross the placenta and are found in fetal tissues, having potentially toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryo toxicity has been noted in animals treated early in pregnancy. Therefore pregnant women will not be allowed to participate in this study~* Female subjects on oral contraceptives~* Contraindication to undergo MRI~* Significant cardiopulmonary, renal or neurological co-morbidities~* Current diagnosis of major depression, substance abuse, or other psychiatric disorders;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline (Type: EXPERIMENTAL): oral Minocycline 100 mg twice a day for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).